Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies

J Clin Oncol. 2005 Oct 1;23(28):7152-60. doi: 10.1200/JCO.2005.01.214.

Abstract

Purpose: To evaluate the impact of tumor location, clinical parameters, and therapy on neurocognitive, neuroendocrine, and functional outcomes in children < or = 3 years old with intracranial CNS malignancies who survived at least 2 years after diagnosis.

Patients and methods: Records were retrospectively reviewed for 194 children diagnosed from 1985 to 1999 at St Jude Children's Research Hospital (Memphis, TN).

Results: The median age at diagnosis was 1.8 years (range, 0.1 to 3.5 years). Median follow-up was 7.64 years (2.0 to 19.4 years). Tumors were infratentorial (102), diencephalic (53), and hemispheric (39); 47% required ventriculoperitoneal shunts, 36% developed seizure disorders, and 20% developed severe ototoxicity. Therapy included no radiation therapy (RT) in 57 (30%), local RT in 87 (45%), and craniospinal irradiation (CSI) in 49 (25%). Overall survival at 10 years was 78 +/- 4%. In a longitudinal analysis of 126 patients with at least one neurocognitive evaluation (NE), the mean rate of intelligence quotient (IQ) change for patients who received CSI (-1.34 points per year) and local RT (-0.51 points per year) was significantly different from the no RT group (0.91 points per year; P = .005 and P = .036, respectively). Patients with hemispheric tumors had a significantly greater IQ decline (-1.52 points per year) than those with midline tumors (0.59 points per year; P = .038). Among those with NE > or = 5 years after diagnosis, 71.4% of CSI recipients compared with 23% of local RT recipients had IQ less than 70 (P = .021). Patients undergoing CSI were more likely to develop endocrinopathies (P < .0001) and to require special education (P = .0007).

Conclusion: In young children with CNS tumors, CSI and hemispheric location are associated with significant declines in IQ scores.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Age of Onset
  • Central Nervous System Neoplasms / pathology*
  • Central Nervous System Neoplasms / therapy*
  • Child
  • Child, Preschool
  • Cognition Disorders / etiology*
  • Endocrine System Diseases / etiology
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Intelligence Tests
  • Male
  • Neuropsychological Tests
  • Prognosis
  • Retrospective Studies
  • Survival Analysis